Ovarian Cancer

In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.

ctDNA offers clinicians the potential to determine whether to proceed with or discontinue PARP inhibitor maintenance therapy in patients with recurrent epithelial ovarian cancer.

Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

Rezatapopt treatment delivered responses with acceptable toxicity in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations.

Olaparib plus cediranib did not improve survival compared with chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

The FDA orphan drug designation qualifies the sponsor of avutometinib for tax credits for clinical trials, exemption from user fees, and potential market exclusivity.

The first-in-human study that has received FDA clearance will investigate the novel autologous Innocell vaccine in stage III/IV ovarian cancer.

Findings from the phase 3b OReO study showed that patients with ovarian cancer who previously received a PARP inhibitor benefitted from a rechallenge with olaparib.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark S. Shahin, MD, discussed with participants how they use the individualized dose of niraparib and manage adverse events in patients with advanced ovarian cancer.

NK010 represents a promising advancement in the landscape of natural killer cell-based immunotherapy across a variety of cancer types.

RC88 is a mesothelin-targeting antibody-drug conjugate that offers a novel approach to treating platinum-resistant ovarian, fallopian tube, and peritoneal cancers.

The FDA has approved the new drug application of a ready-to-dilute formulation of a treatment for breast and ovary adenocarcinoma.

In an interview with Targeted Oncology, Eirwen M. Miller, MD, discussed the dynamic landscape of ovarian cancer treatment.

The FDA has granted priority review to the supplemental biologics application of mirvetuximab soravtansin-gynx for the treatment of patients with platinum-resistant ovarian cancer.

Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Holloway, MD, explored the state of PARP inhibitors for patients with advanced ovarian cancer including the PRIMA trial of niraparib.

The combination of tumor-infiltrating lymphocytes and chemotherapy showed a robust response rate and improvements in progression-free survival in a phase 1/2 study.

Findings from a phase 1 trial shows the early promise of an ENB-003 and pembrolizumab regimen for the treatment of platinum refractory or resistant ovarian cancer.

Findings from the phase 2 RAMP 201 trial show avutometinib plus defactinib demonstrates robust efficacy in patients with recurrent low-grade serious ovarian cancer.

Retrospective data shows that a multidisciplinary surgical approach may improve survival in patients with ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, David M. O'Malley, MD, discussed with participants their experiences with using PARP inhibitors in patients with advanced ovarian cancer.

The OPEB-01 trial showed a potential maintenance role for olaparib, pembrolizumab, and bevacizumab in patients who responded to chemotherapy after platinum-sensitive recurrence to ovarian cancer.

The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Leslie M. Randall, MD, MAS, evaluated the outcomes of the PRIMA/ENGOT-OV26/GOG-3012 study of niraparib as primary maintenance therapy for patients with ovarian cancer.

The addition of PARP inhibitors for the treatment of patients with BRCA-mutated advanced ovarian cancer has provided clinicians with a stronger set of treatment options. Looking at how the BRCA mutation responds to these inhibitors is then vital to deciding the patient’s treatment path.

The fast track designation for AVB-001 granted by the FDA recognizes its potential as a treatment option for patients with relapsed/refractory ovarian cancer.

Results of the phase 3 MIRASOL study evaluating mirvetuximab soravtansine for platinum-resistant ovarian cancer will be announced at an upcoming meeting.

Findings from a phase 1 support the fast track designation given by the FDA to IDE161, a potent, selective, small-molecule inhibitor of PARG, for patients with BRCA1/2 mutant ovarian cancer.